Medical/Pharmaceuticals
HistoSonics Announces Agreement with GE Healthcare
HistoSonics Breakthrough Liver Therapy System to Utilize GE's LOGIQ™ E10 for Real-Time Imaging Guidance and Treatment Verification MINNEAPOLIS, May 23, 2022 /PRNewswire/ -- HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agre...
2022-05-23 21:00
2750
New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer
HANGZHOU, China and HONG KONG, May 23, 2022 /PRNewswire/ -- New Horizon Health (6606.HK) and Prenetics Group Limited (Nasdaq: PRE, "Prenetics") has announced a strategic partnership to launch ColoClear by Circle (ColoClear), the "First Colorectal Cancer Screening Test approved inChina", in Hong K...
2022-05-23 20:46
3818
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
The latest geographic growth increases Medison's global footprint across 25
countries in four continents, further strengthening its commercial offering
PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ -- Medison Pharma
2022-05-23 20:28
3116
Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2022-05-23 10:10
2660
Tulip Partners with Stanley Black & Decker on Global Operations Platform
* Platform to provide digital manufacturing solutions for Stanley Black & Decker operations * Jane Arnold, Vice President of Manufacturing Technology at Stanley Black & Decker, to join Tulip's Board of Directors BOSTON, May 21, 2022 /PRNewswire/ -- Tulip Interfaces ("Tulip") announced today t...
2022-05-21 03:53
8297
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini")...
2022-05-21 01:19
9524
Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias
EPLive 2022 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, May 20, 2022 /PRNewswire/ -- On June 2 and 3, 2022, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its sixth international symposium on complex a...
2022-05-20 20:08
3453
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
* Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients * PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in theESR1 mutation population * Data d...
2022-05-20 16:17
3014
Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment inJune 2022. T...
2022-05-20 14:56
2332
Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
GAITHERSBURG, Md. and SUZHOU, China, May 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company's Executive Director and Chief Medical O...
2022-05-20 12:31
2783
Clinical trial results of Belief BioMed's hemophilia B gene therapy drug candidate BBM-H901 published in The Lancet Haematology
SHANGHAI, May 20, 2022 /PRNewswire/ -- The early phase clinical trial results of BBM-H901, the first intravenously injectable hemophilia B gene therapy product developed and tested inAsia, are published in The Lancet Haematology, a top international journal in hematology. https://www.thelancet....
2022-05-20 10:43
3668
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL") for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5...
2022-05-19 23:28
3396
All Border Ports in Guangxi Commenced Normal Operations
NANNING, China, May 19, 2022 /PRNewswire/ -- Statistics from the Department of Commerce of Guangxi Zhuang Autonomous Region show that during the May Day holiday in 2022, a total of 3,344 vehicles entered and exited throughGuangxi border highway ports, including 1,601 and 1,743 vehicles leaving an...
2022-05-19 21:39
2356
Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment-Published in the European Journal of Cancer
* Study findings show that Lunit's AI-powered PD-L1 TPS analyzer minimizes interpretation discrepancy among pathologists * AI-assisted PD-L1 TPS reading using Lunit SCOPE PD-L1 leads to better prediction of therapeutic outcomes in non-small cell lung cancer patients * In April 2022, Lunit SC...
2022-05-19 21:00
1159
CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays
This acquisition solidifies CellCarta's leadership position in proteomics serviceswith a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein quantification covering a comprehensive range of immuno-onc...
2022-05-19 20:30
1527
4C Medical Technologies Presents Data from the Global Clinical Experience for the AltaValve Early Feasibility Study at AATS 2022
MINNEAPOLIS, May 19, 2022 /PRNewswire/ -- 4C Medical Technologies, Inc. ("4C Medical" or the "Company"), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, presented its global clinical experience from its initial A...
2022-05-19 20:06
2062
Berry Oncology Launches an Innovative Self-Iterative "HIFI" System
BEIJING, May 18, 2022 /PRNewswire/ -- Berry Oncology, a leading company in the global industry for genetic testing and early screening of tumors, recently launched a HIFI system. The HIFI system consists of HIFI-det liquid biopsy technology and the corresponding HIFI-cal series of algorithms. W...
2022-05-19 09:00
2315
FSP, the Top Brand of Power Supply in Five Application Fields
-Edge Computing/Medical/Smart Energy/Gaming/PD Charger- TAIPEI, May 19, 2022 /PRNewswire/ -- FSP Group, the world's leading high-performance ODM & Modified STD power supply manufacturer, today unveils the next wave of products designed with bleeding-edge technology that outperforms their rivals....
2022-05-19 08:30
2778
PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding
BOSTON, May 19, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The cente...
2022-05-19 04:56
2529
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
VANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils deLyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous ...
2022-05-18 20:00
3802
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25
Animated Life in Yunnan
[Picked up by 281 media titles]
2024-04-18 14:00
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
9172
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
2024-04-18 21:26
8839
Animated Life in Yunnan
2024-04-18 14:00
7829
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
7751